Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Ind-Swift Laboratories

NSEI:INDSWFTLAB
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
INDSWFTLAB
NSEI
₹1B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Ind-Swift Laboratories has significant price volatility in the past 3 months.
INDSWFTLAB Share Price and Events
7 Day Returns
6.2%
NSEI:INDSWFTLAB
7.9%
IN Pharmaceuticals
-3.6%
IN Market
1 Year Returns
-38.5%
NSEI:INDSWFTLAB
-14.9%
IN Pharmaceuticals
-32.1%
IN Market
INDSWFTLAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ind-Swift Laboratories (INDSWFTLAB) 6.2% 38.2% -10.6% -38.5% -41.6% -42.4%
IN Pharmaceuticals 7.9% -9.6% -7.2% -14.9% -24.7% -36.3%
IN Market -3.6% -25.1% -30.2% -32.1% -24.1% -15.2%
1 Year Return vs Industry and Market
  • INDSWFTLAB underperformed the Pharmaceuticals industry which returned -14.9% over the past year.
  • INDSWFTLAB underperformed the Market in India which returned -32.1% over the past year.
Price Volatility
INDSWFTLAB
Industry
5yr Volatility vs Market

Value

 Is Ind-Swift Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ind-Swift Laboratories to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ind-Swift Laboratories.

NSEI:INDSWFTLAB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 22.2%
Perpetual Growth Rate 10-Year IN Government Bond Rate 6.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NSEI:INDSWFTLAB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 6.5%
Equity Risk Premium S&P Global 7.9%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 35%) (805.04%))
3.195
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 6.48% + (2 * 7.85%)
22.18%

Discounted Cash Flow Calculation for NSEI:INDSWFTLAB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ind-Swift Laboratories is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NSEI:INDSWFTLAB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 22.18%)
2020 1,326.21 Est @ 8.62% 1,085.45
2021 1,432.05 Est @ 7.98% 959.31
2022 1,539.89 Est @ 7.53% 844.28
2023 1,650.99 Est @ 7.22% 740.88
2024 1,766.48 Est @ 6.99% 648.79
2025 1,887.31 Est @ 6.84% 567.34
2026 2,014.37 Est @ 6.73% 495.61
2027 2,148.45 Est @ 6.66% 432.64
2028 2,290.33 Est @ 6.6% 377.48
2029 2,440.72 Est @ 6.57% 329.24
Present value of next 10 years cash flows ₹6,481.00
NSEI:INDSWFTLAB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₹2,440.72 × (1 + 6.48%) ÷ (22.18% – 6.48%)
₹16,553.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹16,553.38 ÷ (1 + 22.18%)10
₹2,232.98
NSEI:INDSWFTLAB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹6,481.00 + ₹2,232.98
₹8,713.98
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹8,713.98 / 59.09
₹147.48
NSEI:INDSWFTLAB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in NSEI:INDSWFTLAB represents 0.98451x of BSE:532305
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98451x
Value per Share
(Listing Adjusted, INR)
= Value per Share (INR) x Listing Adjustment Factor
= ₹ 147.48 x 0.98451
₹145.19
Value per share (INR) From above. ₹145.19
Current discount Discount to share price of ₹22.25
= -1 x (₹22.25 - ₹145.19) / ₹145.19
84.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ind-Swift Laboratories is available for.
Intrinsic value
>50%
Share price is ₹22.25 vs Future cash flow value of ₹145.19
Current Discount Checks
For Ind-Swift Laboratories to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ind-Swift Laboratories's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ind-Swift Laboratories's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ind-Swift Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ind-Swift Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:INDSWFTLAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in INR ₹-15.43
BSE:532305 Share Price ** BSE (2020-04-03) in INR ₹22.6
India Pharmaceuticals Industry PE Ratio Median Figure of 109 Publicly-Listed Pharmaceuticals Companies 11.66x
India Market PE Ratio Median Figure of 2,614 Publicly-Listed Companies 9.41x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ind-Swift Laboratories.

NSEI:INDSWFTLAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:532305 Share Price ÷ EPS (both in INR)

= 22.6 ÷ -15.43

-1.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ind-Swift Laboratories is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
  • Ind-Swift Laboratories is loss making, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Ind-Swift Laboratories's expected growth come at a high price?
Raw Data
NSEI:INDSWFTLAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Pharmaceuticals Industry PEG Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 1.03x
India Market PEG Ratio Median Figure of 400 Publicly-Listed Companies 0.8x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ind-Swift Laboratories, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ind-Swift Laboratories's assets?
Raw Data
NSEI:INDSWFTLAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in INR ₹124.39
BSE:532305 Share Price * BSE (2020-04-03) in INR ₹22.6
India Pharmaceuticals Industry PB Ratio Median Figure of 135 Publicly-Listed Pharmaceuticals Companies 1.07x
India Market PB Ratio Median Figure of 3,613 Publicly-Listed Companies 0.63x
NSEI:INDSWFTLAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:532305 Share Price ÷ Book Value per Share (both in INR)

= 22.6 ÷ 124.39

0.18x

* Primary Listing of Ind-Swift Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ind-Swift Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Ind-Swift Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ind-Swift Laboratories has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ind-Swift Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ind-Swift Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ind-Swift Laboratories expected to grow at an attractive rate?
  • Unable to compare Ind-Swift Laboratories's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ind-Swift Laboratories's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Ind-Swift Laboratories's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:INDSWFTLAB Future Growth Rates Data Sources
Data Point Source Value (per year)
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 25.8%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 9.5%
India Market Earnings Growth Rate Market Cap Weighted Average 19.2%
India Market Revenue Growth Rate Market Cap Weighted Average 8.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:INDSWFTLAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:INDSWFTLAB Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-12-31 7,977 -734
2019-09-30 7,992 1,406 -211
2019-06-30 7,872 -35
2019-03-31 7,785 -643 384
2018-03-31 7,769 731 220
2017-03-31 7,142 956 -391

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ind-Swift Laboratories is high growth as no earnings estimate data is available.
  • Unable to determine if Ind-Swift Laboratories is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:INDSWFTLAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ind-Swift Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:INDSWFTLAB Past Financials Data
Date (Data in INR Millions) EPS *
2019-12-31 -15.43
2019-09-30 -4.44
2019-06-30 -0.74
2019-03-31 8.22
2018-03-31 4.88
2017-03-31 -9.20

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ind-Swift Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Ind-Swift Laboratories is trading at Ind-Swift Laboratories'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Ind-Swift Laboratories's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Ind-Swift Laboratories's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ind-Swift Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ind-Swift Laboratories has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ind-Swift Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ind-Swift Laboratories's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ind-Swift Laboratories does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Ind-Swift Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ind-Swift Laboratories's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ind-Swift Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ind-Swift Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:INDSWFTLAB Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7,977.13 -734.24 1,020.56
2019-09-30 7,991.96 -210.90 1,011.71
2019-06-30 7,871.71 -35.42 928.59
2019-03-31 7,784.91 384.40 981.12
2018-03-31 7,769.12 219.76 962.93
2017-03-31 7,141.92 -391.34 765.45
2016-03-31 6,641.15 -586.88 694.46
2015-03-31 6,778.32 -1,193.68 570.78
2014-03-31 9,738.37 -1,220.12 866.92 77.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ind-Swift Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Ind-Swift Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • It is difficult to establish if Ind-Swift Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ind-Swift Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ind-Swift Laboratories has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ind-Swift Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ind-Swift Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ind-Swift Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ind-Swift Laboratories's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Ind-Swift Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ind-Swift Laboratories Company Filings, last reported 3 months ago.

NSEI:INDSWFTLAB Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 5,711.01 10,750.26 124.75
2019-09-30 5,711.01 10,750.26 124.75
2019-06-30
2019-03-31 6,039.32 11,154.54 299.68
2018-03-31 5,532.40 10,830.64 94.47
2017-03-31 5,313.23 12,424.12 161.26
2016-03-31 5,174.25 14,572.34 225.78
2015-03-31 5,948.54 14,128.81 198.37
2014-03-31 7,252.34 13,553.68 205.86
  • Ind-Swift Laboratories's level of debt (188.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (223.2% vs 188.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.
X
Financial health checks
We assess Ind-Swift Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ind-Swift Laboratories has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ind-Swift Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ind-Swift Laboratories dividends.
If you bought ₹2,000 of Ind-Swift Laboratories shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ind-Swift Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ind-Swift Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:INDSWFTLAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 77 Stocks 1%
India Market Average Dividend Yield Market Cap Weighted Average of 1419 Stocks 2%
India Minimum Threshold Dividend Yield 10th Percentile 0.4%
India Bottom 25% Dividend Yield 25th Percentile 1%
India Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:INDSWFTLAB Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2012-08-28 0.000 0.000
2012-06-06 0.000 0.000
2011-09-26 1.000 1.079
2010-08-24 1.000 0.966
2009-06-29 1.000 1.566
2009-06-01 1.000 2.348

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ind-Swift Laboratories has not reported any payouts.
  • Unable to verify if Ind-Swift Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ind-Swift Laboratories's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ind-Swift Laboratories has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ind-Swift Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ind-Swift Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ind-Swift Laboratories has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ind-Swift Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nav Munjal
COMPENSATION ₹18,000,000
AGE 67
CEO Bio

Mr. Nav Rattan Munjal has been a Managing Director of Ind-swift Laboratories Ltd. since March 29, 2001 and serves as its Co-Chief Executive Officer. He served as President of Indian Drug Manufacturers’ Association until January 2012. He has been Acting Chairman of the Board at Ind-swift Laboratories Ltd. from April 2008 to April 23, 2019. He was the Vice Chairman at Ind-swift Laboratories Ltd. from April 2008 to April 23, 2019. He served as Non-Executive Vice Chairman of Ind-Swift Ltd until September 2, 2019 and has been its Non Executive Director since December 11, 1986. He has been an Executive Director of Ind-swift Laboratories Ltd., since April 1, 1995.

CEO Compensation
  • Nav's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Nav's remuneration is higher than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Ind-Swift Laboratories management team in years:

10.1
Average Tenure
37
Average Age
  • The average tenure for the Ind-Swift Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Nav Munjal

TITLE
Acting Chairman & MD
COMPENSATION
₹18M
AGE
67

Himanshu Jain

TITLE
Joint MD & Whole Time Director
COMPENSATION
₹18M
AGE
37
TENURE
10.1 yrs

Rishav Mehta

TITLE
Executive Director
COMPENSATION
₹5M
AGE
28

Gagan Aggarwal

TITLE
Chief Financial Officer
TENURE
1.6 yrs

Lalit Wadhwa

TITLE
Chief Operating Officer
TENURE
10.1 yrs

Lovekesh Mahajan

TITLE
Chief Accounts Officer

Pardeep Verma

TITLE
Assistant VP of Corporate Affairs

Atul Chaubey

TITLE
Group Head of Human Resources

Vikas Narendra

TITLE
President of US Operations

Sandeep Singh

TITLE
Senior Vice President of Procurement
Board of Directors Tenure

Average tenure and age of the Ind-Swift Laboratories board of directors in years:

3
Average Tenure
50.5
Average Age
  • The tenure for the Ind-Swift Laboratories board of directors is about average.
Board of Directors

Nav Munjal

TITLE
Acting Chairman & MD
COMPENSATION
₹18M
AGE
67
TENURE
1 yrs

Himanshu Jain

TITLE
Joint MD & Whole Time Director
COMPENSATION
₹18M
AGE
37
TENURE
9.6 yrs

Rishav Mehta

TITLE
Executive Director
COMPENSATION
₹5M
AGE
28
TENURE
10.1 yrs

Sahil Munjal

TITLE
President of Operations & Special Assignments & Executive Director
TENURE
0.2 yrs

Prabhat Khurana

TITLE
Independent Director
COMPENSATION
₹83K
TENURE
5.1 yrs

Sri Sharma

TITLE
Independent Director
COMPENSATION
₹78K
AGE
64
TENURE
7.6 yrs

Ashwani Vig

TITLE
Independent Director
COMPENSATION
₹68K
TENURE
0.2 yrs

Neerja Chathley

TITLE
Independent Woman Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Ind-Swift Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ind-Swift Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Those Who Purchased Ind-Swift Laboratories (NSE:INDSWFTLAB) Shares A Year Ago Have A 62% Loss To Show For It

Investing in stocks comes with the risk that the share price will fall. … Unfortunately, shareholders of Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) have suffered share price declines over the last year. … Even though the Ind-Swift Laboratories share price is down over the year, its EPS actually improved.

Simply Wall St -

Why Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) CEO Pay Matters To You

Check out our latest analysis for Ind-Swift Laboratories How Does Nav Munjal's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Ind-Swift Laboratories Limited has a market cap of ₹1.7b, and is paying total annual CEO compensation of ₹18m. … We examined the amount Ind-Swift Laboratories Limited pays its CEO, and compared it to the amount paid by similar sized companies.

Simply Wall St -

Do Directors Own Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … Ind-Swift Laboratories is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Is Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) CEO Overpaid Relative To Its Peers?

Nav Munjal is the CEO of Ind-Swift Laboratories Limited (NSE:INDSWFTLAB). … How Does Nav Munjal's Compensation Compare With Similar Sized Companies. … According to our data, Ind-Swift Laboratories Limited has a market capitalization of ₹2.2b, and pays its CEO total annual compensation worth ₹18m.

Simply Wall St -

Could Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Investor Composition Influence The Stock Price?

The big shareholder groups in Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) have power over the company. … Ind-Swift Laboratories is not a large company by global standards. … institutional investors have not yet purchased much of the company

Simply Wall St -

Should You Be Concerned About Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Historical Volatility?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful.

Simply Wall St -

How Does Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Affect Your Portfolio Returns?

The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market. … Not every stock is exposed to the same level of market risk. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

Does Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) PE Ratio Signal A Buying Opportunity?

and want to begin learning the link between Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)’s fundamentals and stock market performance. … Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) trades with a trailing P/E of 20.2x, which is lower than the industry average of 24.4x. … While this makes INDSWFTLAB appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio

Simply Wall St -

Who Are Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Major Shareholders?

This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Another group of owners that a potential investor in INDSWFTLAB should consider are private companies, with a stake of 30.53%. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership in INDSWFTLAB is not at a level that would concern investors.

Simply Wall St -

What You Must Know About Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Market Risks

A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … Therefore, investors can expect a high beta associated with the size of INDSWFTLAB, but a lower beta given the nature of the industry it operates in. … As a result, this aspect of INDSWFTLAB indicates a higher beta than a similar size company with a lower portion of fixed assets on their balance sheet.

Simply Wall St -

Company Info

Description

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. Its impurities portfolio include acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is headquartered in Manimajra, India.

Details
Name: Ind-Swift Laboratories Limited
INDSWFTLAB
Exchange: NSEI
Founded: 1995
₹1,335,363,036
59,086,860
Website: http://www.indswiftlabs.com
Address: Ind-Swift Laboratories Limited
Shivalik Enclave,
SCO 850,
Manimajra,
Chandigarh, 160101,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 532305 Equity Shares Mumbai Stock Exchange IN INR 16. Jul 1997
NSEI INDSWFTLAB Equity Shares National Stock Exchange of India IN INR 16. Jul 1997
Number of employees
Current staff
Staff numbers
0
Ind-Swift Laboratories employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 13:08
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.